Inventor
Kenneth A. Thomas, Jr.
Inventor
Chatham, NJ, US
Overview
Patents· 28 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides33%
A61KPreparations for medical, dental or toiletry purposes21%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations16%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
C12NMicroorganisms or enzymes6%
C07DHeterocyclic compounds4%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
A61LMethods or apparatus for sterilising materials or objects in general1%
B65BMachines, apparatus or devices for, or methods of, packaging articles or materials1%
B65DContainers for storage or transport of articles or materials, e.g. bags, barrels, bottles, boxes, cans, cartons, crates, drums, jars, tanks, hoppers, forwarding containers1%
PatentTitleYear
10,624,952Systems and methods for angiogenic treatment in wound healing20208,983,570'Therapeutic angiogenesis for treatment of the spine'20158,034,772'Inhibitor of vascular endothelial cell growth factor'20117,071,159'Inhibitor of vascular endothelial cell growth factor'20066,933,134'DNA molecules encoding vascular endothelial cell growth factor II subunits'20056,841,367'Human receptor tyrosine kinase, KDR'20056,841,382'Human receptor tyrosine kinase, KDR'20056,569,434'Vascular endothelial cell growth factor C subunit'20036,380,203'Angiogenesis inhibitors'20026,375,929'Gene therapy for inhibition of angiogenesis'20026,359,115'Human receptor tyrosine kinase, KDR'20026,235,741'Angiogenesis inhibitors'20016,228,871'Angiogenesis inhibitors'20016,204,011'Human receptor tyrosine kinase, KDR'20016,180,107'Vascular endothelial cell growth factor II'20016,140,073'Vascular endothelial cell growth factor C subunit'20005,994,300'Vascular endothelial cell growth factor C subunit'19995,861,484'Inhibitor of vascular endothelial cell growth factor'19995,806,281'Tear tape adapted for complete sealing of package overwrap'19985,726,152'Vascular endothelial cell growth factor II'19985,712,380'DNA encoding a soluble VEGF inhibitor'19985,532,343'Purification and characterization of a glioma-derived growth factor having vascular endothelial cell growth promoting activity'19965,409,897'Cysteine-modified acidic fibroblast growth factor and methods of use'19955,401,832'Brain derived and recombinant acidic fibroblast growth factor'19955,338,840'DNA encoding glioma-derived growth factor having vascular endothelial cell growth promoting activity'19945,312,911'Cysteine-modified acidic fibroblast growth factor'19945,223,483'Cysteine-modified acidic fibroblast growth factor'19934,444,760'Purification and characterization of a protein fibroblast growth factor'1984Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1984–2006Patents assigned to MERCK & CO INC (24)· patent assignee history
1984Based in Cranford, NJ, US· patent location history
1993–2020Based in Chatham, NJ, US· patent location history
1998Based in Winnipeg, CA· patent location history
2015–2020Patents assigned to CARDIOVASCULAR BIOTHERAPEUTICS INC (2)· patent assignee history
2015Patents assigned to BAHRI SHADFAR (1)· patent assignee history
2015Patents assigned to GARDNER VANCE (1)· patent assignee history
2015Patents assigned to JACOBS JOHN W (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MERCK & CO INC | 24 | 1984–2006 |
| CARDIOVASCULAR BIOTHERAPEUTICS INC | 2 | 2015–2020 |
| BAHRI SHADFAR | 1 | 2015 |
| GARDNER VANCE | 1 | 2015 |
| JACOBS JOHN W | 1 | 2015 |
Locations
| Location | Patents | Span |
|---|---|---|
| Chatham, New Jersey, US | 26 | 1993–2020 |
| Winnipeg, CA | 1 | 1998 |
| Cranford, New Jersey, US | 1 | 1984 |